Addiction

Papers
(The H4-Index of Addiction is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Issue Information181
Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling161
An Addiction series on regional perspectives on addiction‐related problems157
104
Risk of readmission among individuals with cannabis use disorder during a 15‐year cohort study: the impact of socio‐economic factors and psychiatric comorbidity95
Commentary on Lange et al.: Acute alcohol use before suicide—is it contributing to an increase in suicide rates in the United States?89
National profile on substance use, substance use‐related problems and policy: The case of Chile89
77
Impulsivity behaviors and white matter mediate the relationship between genetic risk for cannabis use disorder and early cannabis use in adolescents77
Society for the Study of Addiction Annual Conference 202477
Opioid overdose deaths and the expansion of opioid agonist treatment: a population‐based prospective cohort study76
Technology‐mediated just‐in‐time adaptive interventions (JITAIs) to reduce harmful substance use: a systematic review74
Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data73
Rare but relevant series69
The use of financial incentives for smoking cessation in pregnant women: A parallel‐group randomised controlled trial protocol69
Recent decline in Chinese alcohol production and consumption: Potential contributing factors and the role of globally recommended measures66
Commentary on Stull et al.: Considering person‐specific heterogeneity when modeling time‐varying trends63
Austin Bradford Hill’s ‘Environment and disease: Association or causation’60
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial59
Cannabis: Global Histories by Lucas Richert and James H. Mills, editors57
Education matters: longitudinal pathways to mid‐life heavy drinking in a national cohort of black Americans57
How substance use prevention research gets used in United States federal policy57
Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness53
Naloxone administration—no balance without titration53
Quantifying alcohol‐attributable disability‐adjusted life years to others than the drinker in Aotearoa/New Zealand: A modelling study based on administrative data51
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms50
Will Australia's tightened prescription system reduce nicotine vaping among young people?50
Commentary on Nower et al: The Pathways Model should apply to non‐clinical gambling patterns49
Nicotine strength of e‐liquids used by adult vapers in Great Britain: A population survey 2016 to 202447
Non‐alcoholic beverage consumption among US adults who consume alcohol46
Did the under‐reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased?44
Structure and stability of internet gaming disorder from childhood to late adolescence: A 5‐wave birth cohort study41
Assessing the impacts of alcohol outlets on crime as a natural experiment: agglomeration, churning and spatial effects41
Does recreational cannabis legalization change cannabis use patterns? Evidence from secondary school students in Uruguay40
Use of cessation products, e‐cigarettes and cigarette cessation outcomes among adults with substance use problems: Results from 2013–2021 (Waves 1–6) of the Population Assessment of Tobacco and Health40
Estimating recent trends in alcohol sales in the United Kingdom from alcohol duty revenue40
39
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial39
Chronic obstructive pulmonary disease in heroin users: An underappreciated issue with clinical ramifications38
0.24411702156067